Stock AnalizIntellia Therapeutics, Inc. NTLA
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2016 · data as of November 13, 2026
Intellia Therapeutics, Inc. (NTLA) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $53M and net income of -$426M, a net margin of -805.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 3% a year, a 5-year average ROIC of -33%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53M | $68M | $58M | $36M | $52M | $33M | $58M | $43M | $30M | $26M | $16M |
| Net income | -$426M | -$413M | -$519M | -$481M | -$474M | -$268M | -$134M | -$474M | -$85M | -$68M | -$32M |
| Free cash flow | -$358M | -$396M | -$355M | -$408M | -$347M | -$238M | -$53M | -$110M | -$68M | -$75M | $30M |
| EPS (diluted) | $-3.34 | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | $-2.11 | $-1980.00 | $-1880.00 | $-1420.00 |
| Net margin | -805.7% | -609.8% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -1100.1% | -280.4% | -258.6% | -192.0% |
| ROIC | — | -45.6% | -39.0% | -34.9% | -26.5% | -19.0% | -19.1% | -29.1% | -25.8% | -18.3% | -15.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 18 analysts is $22.78, 135% above the current price; targets range from $8.00 to $61.00; the consensus rating is “Buy”; expected EPS is $-3.27 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Intellia Therapeutics pay a dividend?
Not currently.
Is Intellia Therapeutics a good stock to buy?
We do not give buy or sell advice. Intellia Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.